In Silico Modeling of Drugs Against Coronaviruses

Dr. Kunal Roy is Professor & Head of the Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India (https://sites.google.com/site/kunalroyindia). He has been a recipient of the Commonwealth Academic Staff Fellowship (University of Manchester, 2007) and Marie Curie International Incoming Fellowship (University of Manchester, 2013) and was a former visiting scientist of Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milano. Italy. The field of his research interest is Quantitative Structure-Activity Relationship (QSAR) and Molecular Modeling with application in Drug Design, Property Modeling, and Predictive Ecotoxicology. Dr. Roy has published more than 300 research articles (ORCID: http://orcid.org/0000-0003-4486-8074) in refereed journals (current SCOPUS h index 43; total citations till date 9562). He has also coauthored two QSAR related books (with Academic Press and Springer Nature), edited six QSAR books (Springer Nature, Academic Press, and IGI Global), and published more than ten book chapters. Dr. Roy is the Co-Editor-in-Chief of Molecular Diversity (Springer Nature) and Editor-in-Chief of International Journal of Quantitative Structure-Property Relationships (IGI Global). Dr. Roy serves on the Editorial Boards of several international journals including (1) European Journal of Medicinal Chemistry (Elsevier); (2) Journal of Molecular Graphics and Modelling (Elsevier); (3) Computational and Structural Biotechnology Journal (Elsevier); (4) Chemical Biology and Drug Design (Wiley); (5) Expert Opinion on Drug Discovery (Informa); (6) Letters in Drug Design and Discovery (Bentham); and (7) Current Computer-Aided Drug Design (Bentham). Apart from this, Prof. Roy is a regular reviewer for QSAR papers in the journals like Chemosphere (Elsevier), Journal of Hazardous Materials (Elsevier), Ecotoxicologyand Environmental Safety (Elsevier), Journal of Chemical Information and Modeling (ACS), ACS Omega (ACS),  RSC Advances (RSC), Molecular Informatics (Wiley), SAR and QSAR in Environmental Research (T&F), etc. Prof. Roy has been recipient of several awards including the AICTE Career Award (2003-04), DST Fast Track Scheme for Young Scientists (2005), Bioorganic and Medicinal Chemistry Most Cited Paper 2003-2006, 2004-2007, and 2006-2009 Awards from Elsevier, The Netherlands,  Bioorganic and Medicinal Chemistry Letters Most Cited Paper 2006-2009 Award from Elsevier, The Netherlands, Professor R. D. Desai 80th Birthday Commemoration Medal & Prize (2017) from Indian Chemical Society, etc. Prof. Roy has been a participant in the EU funded projects nanoBRIDGES and IONTOX apart from several national government funded projects (UGC, AICTE, CSIR, ICMR, DBT, DAE). Prof. Roy has recently been placed in the list of Top 2%science-wide author database of the world (World rank 81 in the subfield of Medicinal & Biomolecular Chemistry)  (https://doi.org/10.1371/journal.pbio.3000918).

- Part I Introduction. - History and Recent Advances in Coronavirus Discovery. - The Origin, Transmission, and Clinical Therapies in the Management of Coronavirus Diseases. - Transmission, Medical Consequences, and Prevention/Treatment of COVID-19 Infection. - Molecular-Level Targets for the Development of Therapies Against Coronavirus Diseases. - Candidate Drugs for the Potential Treatment of Coronavirus Diseases. - Part II Tools and Methodologies. - Ligand-Based Approaches for theDevelopment of Drugs Against SARS-CoV-2. - Computational Drug Repurposing for the Development of Drugs Against Coronaviruses. - Computational Methods and Tools for Repurposing of Drugs Against Coronaviruses. - Molecular Multi-target Approach on COVID-19 for Designing Novel Chemicals. - Structural Bioinformatics to Unveil Weaknesses of Coronavirus Spike Glycoprotein Stability. - Protein–Protein Interaction Network for the Identification of New Targets Against Novel Coronavirus. - Nonequilibrium Alchemical Simulations for the Development of DrugsAgainst Covid-19. - Therapeutic and Vaccine Strategies for Stopping the COVID-19 Pandemic Based on Structural and Molecular Modeling Studies of Virus-Ganglioside Interactions. - Discovery of Covalent Drugs Targeting the Key Enzymes of SARS-CoV-2 Using SCARdock. - Machine Learning Techniques for Development of Drugs Against Coronavirus Disease 2019 (COVID-19): A Case Study Protocol. - Part III Case Studies and Literature Reports. - Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. - Recent Perspectives on COVID-19 and Computer-Aided Virtual Screening ofNatural Compounds for the Development of Therapeutic Agents Towards SARS-CoV-2. - Computational Modeling of Protease Inhibitors for the Development of Drugs Against Coronaviruses. - Computational Modeling of ACE2-Mediated Cell Entry Inhibitors for the Development of Drugs Against Coronaviruses. - Computational Modeling of RdRp Inhibitors for the Development of Drugs against Novel Coronavirus (nCoV). - Computational Modeling of Chloroquine Analogues for Development of Drugs Against Novel Coronavirus (nCoV). - Computational Modeling of ACE2 Inhibitors for Development of Drugs Against Coronaviruses. - Deep Learning-Based Drug Screening for COVID-19 and Case Studies. - Virtual Screening of Natural Compounds Targeting Proteases of Coronaviruses and Picornaviruses. - Molecular Simulation–Driven Drug Repurposing for the Identification of Inhibitors Against Non-Structural Proteins of SARS-CoV-2. - Part IV Online Tools and Databases. - Online Tools and Antiviral Databases for the Development of Drugs Against Coronaviruses. - Online Resource and Tools for the Development of Drugs Against Novel Coronavirus. - Drug Databases for Development of Therapeutics Against Coronaviruses.